Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mayur S. Mitra"'
Autor:
Phyllis Chan, Han Ting Ding, Bianca M. Liederer, Jialin Mao, Paula Belloni, Liuxi Chen, Simon S. Gao, Victory Joseph, Xiaoying Yang, Joseph S. Lin, Mayur S. Mitra, Wendy S. Putnam, Angelica Quartino, Rebecca N. Bauer, Lin Pan
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1945-1954 (2021)
Abstract GDC‐0334 is a novel small molecule inhibitor of transient receptor potential cation channel member A1 (TRPA1), a promising therapeutic target for many nervous system and respiratory diseases. The pharmacokinetic (PK) profile and pharmacody
Externí odkaz:
https://doaj.org/article/38338915571446a38eeb11b03b47d34b
Autor:
Han Ting Ding, Wendy S. Putnam, Simon S. Gao, Joseph Lin, Bianca M. Liederer, Jialin Mao, Angelica Quartino, Victory Joseph, Xiaoying Yang, Liuxi Chen, Paula Belloni, Phyllis Chan, Rebecca N. Bauer, Mayur S. Mitra, Lin Pan
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1945-1954 (2021)
Clinical and Translational Science
Clinical and Translational Science
GDC‐0334 is a novel small molecule inhibitor of transient receptor potential cation channel member A1 (TRPA1), a promising therapeutic target for many nervous system and respiratory diseases. The pharmacokinetic (PK) profile and pharmacodynamic (PD
Autor:
Yan Wu, Jean-Michel Vernes, Wei-Ching Liang, Karla Lancaster, Melissa Schutten, Y. Gloria Meng, Gopinath S. Palanisamy, Rutwij A. Dave, Matthew S Holdren, Adeyemi O Adedeji, Fiona Zhong, Mayur S. Mitra, Shannon J. Turley
Publikováno v:
Toxicological Sciences. 175:24-34
Transforming growth factor β (TGFβ) signaling has been recently shown to reduce antitumor response to PD-L1 blockade, leading to a renewed enthusiasm in developing anti-TGFβ therapies for potential combination with cancer immunotherapy agents. Inh
Publikováno v:
Toxicologic pathology. 49(3)
Long-acting delivery platforms for intravitreal therapies are an active area of research in ophthalmic drug development. The aim of these platforms is to decrease the burden of intravitreal therapies for patients, by increasing the period between int
Autor:
Evan A. Thackaberry, Mayur S. Mitra, Lakshmanan Thiruneelakantapillai, Brad Holub, Steven DeMarco
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 117
Novel peptide drugs continue to gain interest as effective modalities against previously undruggable targets. As with any other technology, development and safety assessment of peptides presents with various complex challenges. Additionally, there is
Publikováno v:
Methods in Pharmacology and Toxicology ISBN: 9781071601709
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1b10acaf613d0991449c34dfadb0ee4
https://doi.org/10.1007/978-1-0716-0171-6_12
https://doi.org/10.1007/978-1-0716-0171-6_12
Autor:
Joel P. Bercu, Richard Hutchinson, Kaushik Datta, John C. Pettersen, John Nicolette, Teresa C. Wegesser, Mayur S. Mitra
Publikováno v:
Regulatory Toxicology and Pharmacology. 122:104895
As per the ICH Q3A(R2) and Q3B(R2) regulatory guidelines, safety studies may be needed when an impurity in new drug substances or products is above the qualification threshold, and such qualification studies should be conducted in one nonclinical spe